Multiple dose pharmacokinetics of a new once daily extended release tolterodine formulation versus immediate release tolterodine

Clinical Pharmacokinetics
B Olsson, J Szamosi

Abstract

To determine the multiple dose pharmacokinetics of a new extended release (ER) capsule formulation of tolterodine, compared with the existing immediate release (IR) tablet, in healthy volunteers. Nonblind, randomised, 2-way crossover trial. 19 healthy volunteers (7 females, 12 males), mean age 33 years (range 18 to 55 years). Prior to the study, all volunteers were classified as either extensive or poor metabolisers by cytochrome P450 2D6 genotyping. Volunteers received tolterodine ER 4mg once daily or tolterodine IR 2mg twice daily for 6 days (all doses given as the L-tartrate salt). A washout period of 7 days separated the 2 treatments. Serum concentrations of tolterodine, its active 5-hydroxymethyl metabolite (5-HM) and the active moiety (extensive metabolisers: sum of unbound tolterodine + 5-HM; poor metabolisers: unbound tolterodine) were measured for up to 48 hours post-dose on day 6 (steady state). Tolerability was also determined. 17 volunteers (13 extensive metabolisers, 4 poor metabolisers) completed the study and were evaluable for both treatment periods. The 90% confidence interval for the geometric mean ratio of area under the serum concentration-time curve to 24 hours (AUC24) of the active moiety, for all voluntee...Continue Reading

References

Sep 17, 1977·Lancet·A MahgoubR L Smith
Jan 1, 1992·Clinical Pharmacology and Therapeutics·M L DahlF Sjöqvist
Jan 1, 1990·European Journal of Clinical Pharmacology·G AlvánU Gundert-Remy
Sep 1, 1987·Gastroenterology·R H GooN P Alazraki
Feb 1, 1997·The Journal of Antimicrobial Chemotherapy·D ZakulaR C Goldman
May 1, 1997·Antimicrobial Agents and Chemotherapy·A HsuJ M Leonard
Jun 19, 1998·Clinical Pharmacology and Therapeutics·N BrynneJ Gabrielsson
Apr 17, 1999·Biopharmaceutics & Drug Disposition·I Påhlman, P Gozzi
Oct 30, 1999·International Urogynecology Journal and Pelvic Floor Dysfunction·H P DrutzS Radomski
Mar 15, 2001·Urology·P Van KerrebroeckUNKNOWN Tolterodine Study Group
Mar 28, 2001·Journal of Clinical Pharmacology·B OlssonH Arnberg

❮ Previous
Next ❯

Citations

Oct 6, 2006·Naunyn-Schmiedeberg's Archives of Pharmacology·Martin C Michel, Sharath S Hegde
Nov 17, 2009·European Journal of Clinical Pharmacology·Bimal K MalhotraScott A MacDiarmid
Feb 9, 2010·World Journal of Urology·Maya SchiffersUlrich Mehnert
Oct 2, 2002·Current Urology Reports·H Henry LaiRodney A Appell
Oct 25, 2008·Current Urology Reports·Scott MacDiarmidBimal K Malhotra
Nov 11, 2003·Clinical Pharmacokinetics·David R P Guay
Jul 2, 2009·Clinical Pharmacokinetics·Oxana Doroshyenko, Uwe Fuhr
Nov 12, 2009·Clinical Pharmacokinetics·Shu-Feng Zhou
Aug 9, 2012·Expert Opinion on Drug Metabolism & Toxicology·Umberto Leone Roberti MaggioreSimone Ferrero
Jun 7, 2005·Expert Opinion on Pharmacotherapy·Eric S Rovner
Oct 3, 2006·The Urologic Clinics of North America·Jamie A Kanofsky, Victor W Nitti
May 31, 2008·Journal of the American Geriatrics Society·Marci L ChewGeorges Gharabawi
Feb 9, 2006·British Journal of Pharmacology·Sharath S Hegde
May 10, 2011·Journal of Clinical Pharmacology·Werner SiegmundWilhelm Kirch
Jul 8, 2015·Current Urology Reports·Mauro GacciSergio Serni
Mar 1, 2003·Expert Review of Neurotherapeutics·Philip Van Kerrebroeck
Oct 9, 2004·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Alan D Garely, Lara Burrows
Mar 7, 2007·Clinical Pharmacology and Therapeutics·B K MalhotraP Wicker
Jun 10, 2010·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Masayo OishiToshio Suwa
Sep 14, 2006·Pharmacological Reviews·Sharon J Gardiner, Evan J Begg
Aug 12, 2009·Expert Opinion on Pharmacotherapy·Doreen E Chung, Alexis E Te
Jan 9, 2004·The Journal of Pharmacology and Experimental Therapeutics·Jiesheng KangDavid Rampe

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.